{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:05:29Z","timestamp":1754107529103},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T00:00:00Z","timestamp":1374624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s40261-013-0111-z","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T12:29:58Z","timestamp":1374668998000},"page":"675-683","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of Sublingual Fentanyl Orally Disintegrating Tablets in Patients with Breakthrough Pain: Multicentre Prospective Study"],"prefix":"10.1007","volume":"33","author":[{"given":"Jordi","family":"Guitart","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Ferreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan M.","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Folch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Moya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Rodelas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Tom\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Arilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Coma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Aberasturi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Sintes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Lomb\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,24]]},"reference":[{"key":"111_CR1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(90)90004-W","volume":"41","author":"RK Portenoy","year":"1990","unstructured":"Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273\u201381.","journal-title":"Pain"},{"key":"111_CR2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0304-3959(99)00006-8","volume":"81","author":"RK Portenoy","year":"1999","unstructured":"Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129\u201334.","journal-title":"Pain"},{"key":"111_CR3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1191\/0269216304pm890oa","volume":"18","author":"A Caraceni","year":"2004","unstructured":"Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177\u201383.","journal-title":"Palliat Med"},{"key":"111_CR4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0304-3959(92)90155-5","volume":"50","author":"S Mercadante","year":"1992","unstructured":"Mercadante S, Maddaloni S, Roccella S, et al. Predictive factors in advanced cancer pain treated only by analgesics. Pain. 1992;50:151\u20135.","journal-title":"Pain"},{"key":"111_CR5","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/0885-3924(95)00052-Z","volume":"10","author":"E Bruera","year":"1995","unstructured":"Bruera E, Schoeller T, Wenk R, et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manag. 1995;10:348\u201355.","journal-title":"J Pain Symptom Manag"},{"key":"111_CR6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5055\/jom.2010.0009","volume":"6","author":"R Portenoy","year":"2010","unstructured":"Portenoy R, Bruns D, Shoemaker B, et al. Breakthrough pain in community-dwelling patient with cancer pain and non-cancer pain. Part 1: prevalence and characteristics. J Opioid Manag. 2010;6:97\u2013108.","journal-title":"J Opioid Manag"},{"key":"111_CR7","doi-asserted-by":"crossref","first-page":"E103","DOI":"10.36076\/ppj.2011\/14\/E103","volume":"14","author":"L Manchikanti","year":"2011","unstructured":"Manchikanti L, Singh V, Caraway DL, et al. Breakthrough pain in chronic non-cancer pain: fact, fiction or abuse. Pain Physician. 2011;14:E103\u201317.","journal-title":"Pain Physician"},{"key":"111_CR8","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1526-4637.2010.00891.x","volume":"11","author":"PG Fine","year":"2010","unstructured":"Fine PG, Narayana A, Passik SD. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management. Pain Med. 2010;11:1024\u201336.","journal-title":"Pain Med"},{"key":"111_CR9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0025-6196(11)60748-9","volume":"84","author":"SD Passik","year":"2009","unstructured":"Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84:593\u2013601.","journal-title":"Mayo Clin Proc"},{"key":"111_CR10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jpain.2006.02.003","volume":"7","author":"RK Portenoy","year":"2006","unstructured":"Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic non-cancer pain. J Pain. 2006;7:583\u201391.","journal-title":"J Pain"},{"key":"111_CR11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpainsymman.2007.06.012","volume":"35","author":"G Zeppetella","year":"2008","unstructured":"Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patients\u2019 assessment of time to meaningful pain relief. J Pain Symptom Manag. 2008;35:563\u20137.","journal-title":"J Pain Symptom Manag"},{"key":"111_CR12","first-page":"29","volume":"26","author":"V Sanctis Briggs De","year":"2011","unstructured":"De Sanctis Briggs V. Opioid therapy in cancer patients. Dolor. 2011;26:29\u201336.","journal-title":"Dolor"},{"key":"111_CR13","first-page":"15","volume":"1","author":"AH Shojaei","year":"1998","unstructured":"Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci. 1998;1:15\u201330.","journal-title":"J Pharm Pharm Sci"},{"key":"111_CR14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ejps.2003.07.002","volume":"20","author":"S Brendenberg","year":"2003","unstructured":"Brendenberg S, Duberg M, Lennern\u00e4s B, et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci. 2003;20:327\u201334.","journal-title":"Eur J Pharm Sci"},{"key":"111_CR15","unstructured":"Abstral\u00ae (fentanyl sublingual tablets for breakthrough cancer pain). PT 2011; 36:2\u201328."},{"key":"111_CR16","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1185\/03007990903368310","volume":"25","author":"RL Rauck","year":"2009","unstructured":"Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877\u201385.","journal-title":"Curr Med Res Opin"},{"key":"111_CR17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/0269216309356138","volume":"24","author":"B Lennern\u00e4s","year":"2010","unstructured":"Lennern\u00e4s B, Frank-Lissbrant I, Lennern\u00e4s H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med. 2010;24:286\u201393.","journal-title":"Palliat Med"},{"key":"111_CR18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1185\/03007995.2010.545380","volume":"27","author":"S Nalamachu","year":"2011","unstructured":"Nalamachu S, Hassman D, Wallace MS, et al. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin. 2011;27:519\u201330.","journal-title":"Curr Med Res Opin"},{"key":"111_CR19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1533-2500.2011.00491.x","volume":"12","author":"M Darwish","year":"2012","unstructured":"Darwish M, Xie F. Pharmacokinetics of fentanyl buccal tablet: a pooled analysis and review. Pain Pract. 2012;12:307\u201314.","journal-title":"Pain Pract"},{"key":"111_CR20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1185\/030079906X162818","volume":"23","author":"RK Portenoy","year":"2007","unstructured":"Portenoy RK, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin. 2007;23:223\u201333.","journal-title":"Curr Med Res Opin"},{"key":"111_CR21","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.clinthera.2007.04.007","volume":"29","author":"DM Simpson","year":"2007","unstructured":"Simpson DM, Messina J, Xie F, et al. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:588\u2013601.","journal-title":"Clin Ther"},{"key":"111_CR22","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1526-4637.2010.00939.x","volume":"11","author":"JT Farrar","year":"2010","unstructured":"Farrar JT, Messina J, Xie F, et al. A novel 12-week study, with three randomized double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with non-cancer-related chronic pain. Pain Med. 2010;11:1313\u201327.","journal-title":"Pain Med"},{"key":"111_CR23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jpainsymman.2010.02.009","volume":"40","author":"PG Fine","year":"2010","unstructured":"Fine PG, Messina J, Xie F, et al. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. J Pain Symptom Manag. 2010;40:747\u201360.","journal-title":"J Pain Symptom Manag"},{"key":"111_CR24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5055\/jom.2011.0071","volume":"7","author":"LR Webster","year":"2011","unstructured":"Webster LR, Messina J, Xie F, et al. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain. J Opioid Manag. 2011;7:297\u2013308.","journal-title":"J Opioid Manag"},{"key":"111_CR25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1185\/03007995.2011.554808","volume":"27","author":"S Nalamachu","year":"2011","unstructured":"Nalamachu S, Narayana A, Janka L. Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of non-cancer-related breakthrough pain in opioid-tolerant patients. Curr Med Res Opin. 2011;27:751\u201360.","journal-title":"Curr Med Res Opin"},{"key":"111_CR26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5055\/jom.2010.0010","volume":"6","author":"R Portenoy","year":"2010","unstructured":"Portenoy R, Bruns D, Shoemaker B, et al. Breakthrough pain in community-dwelling patient with cancer pain and non-cancer pain. Part 2: impact on function, mood, and quality of life. J Opioid Manag. 2010;6:109\u201316.","journal-title":"J Opioid Manag"},{"key":"111_CR27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105\u201321.","journal-title":"J Pain"},{"key":"111_CR28","first-page":"207","volume":"18","author":"JM Trinidad","year":"2011","unstructured":"Trinidad JM, Herrera J, Rodr\u00edguez MJ, et al. An\u00e1lisis de efectividad del citrato de fentanilo sublingual en pacientes con dolor irruptivo: estudio Sublime. Rev Soc Esp Dolor. 2011;18:207\u201318.","journal-title":"Rev Soc Esp Dolor"},{"key":"111_CR29","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1185\/03007995.2011.583231","volume":"27","author":"MA \u00dcberall","year":"2011","unstructured":"\u00dcberall MA, M\u00fcller-Schwefe GH. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin. 2011;27:1385\u201394.","journal-title":"Curr Med Res Opin"},{"issue":"suppl.1","key":"111_CR30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/0044011-200929001-00003","volume":"29","author":"A Gatti","year":"2009","unstructured":"Gatti A, Reale C, Occhioni R, et al. Standard therapy with opioids in chronic pain management: Ortiber Study. Clin Drug Invest. 2009;29(suppl.1):17\u201323.","journal-title":"Clin Drug Invest"},{"issue":"Suppl 2","key":"111_CR31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/1158413-S0-000000000-00000","volume":"30","author":"A Gatti","year":"2010","unstructured":"Gatti A, Reale C, Occhioni R, et al. Effects of opioid rotation in chronic pain patients: Ortibarn Study. Clin Drug Invest. 2010;30(Suppl 2):39\u201347.","journal-title":"Clin Drug Invest"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0111-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-013-0111-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0111-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:04:44Z","timestamp":1646179484000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-013-0111-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,24]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["111"],"URL":"https:\/\/doi.org\/10.1007\/s40261-013-0111-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,24]]}}}